GoodRx, Novo Nordisk Offer Ozempic, Wegovy at $499/Month
Until today, Ozempic® has not been available to eligible self-paying patients at this price GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today...
Tag : drug development
MedImpact Offers Low-Cost Ustekinumab Biosimilar
MedImpact Holdings Inc. today announced that it will have access to an unbranded biosimilar ustekinumab-aekn at a significantly lower cost than the reference Stelara® (ustekinumab). The...
FDA Clears VASTHERA to Begin Trial for PAH Drug VTB-10
On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA)...
TandemAI & Perpetual Medicines Merge to Boost AI Drug Discovery
Combined Firm, Known as TandemAI, Will Build on Synergies of Advanced Artificial Intelligence and Computational Platforms for Small Molecule and Peptide-Based Therapeutics TandemAI, a company...
Harbour BioMed, Otsuka Partner on BCMAxCD3 T-Cell Engagers
Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a...
Actio Biosciences Raises $66M Series B for Genetics-Driven Therapeutics
Financing co-led by Regeneron Ventures and Deerfield Management will support advancement of lead programs, ABS-1230 and ABS-0871 Phase 1 trial initiation expected in second half...
Tracer Biotech Partners with QIAGEN to Advance Blood MRD Testing
Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA)...
Asgard Therapeutics Adds Top Experts to Board, Boosting Drug & Cancer Immunotherapy
Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces the appointments of Dr Cristina Csimma as an independent member of...
Mazdutide Obesity Study in China Published in NEJM
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic and...
BioCentury Hosts Grand Rounds in Chicago: Science Meets Investment
Join VCs, academic innovators and biopharma executives to connect, collaborate and accelerate innovation at the forefront of drug R&D Top decision-makers from across the biopharma...
Lundbeck to Share MSA Pipeline Data at International Congress
H. Lundbeck A/S (Lundbeck) will present key pipeline data and patient perspectives from the phase II AMULET trial, investigating amlenetug as a potential new treatment...
Rare Disease Breakthroughs: How Fast-Tracking is Changing the Game
Explore how fast-tracking approvals are driving rare disease breakthroughs, offering faster treatments and new hope for patients worldwide. Table of Contents1. The Challenge of Rare...
Artis BioSolutions Acquires Landmark Bio, Emerges from Stealth
Landmark acquisition positions Artis to revolutionize advanced therapy manufacturing and commercialization Artis BioSolutions, a company founded to streamline the discovery, development and production of genetic...
Palleon Announces NMPA IND Clearance for Phase 2 Trial of E-602
Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced that the China National Medical Products Administration (NMPA) has...
The Future of Medicine: VoxCell BioInnovation on All Access
All Access with Andy Garcia explores how VoxCell BioInnovation Inc. is revolutionizing drug development with 3D bioprinting, paving the way for personalized medicine and an end to...